Prelude Therapeutics (PRLD) Free Cash Flow Growth (3y) (2022 - 2026)
Prelude Therapeutics (PRLD) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 31.42% |
| 10 | Prelude Therapeutics | 330.91 Mn | 186.31 Mn | - | 11.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.18% |
| Dec 31, 2025 | 44.52% |
| Sep 30, 2025 | -0.11% |
| Jun 30, 2025 | -9.59% |
| Mar 31, 2025 | -15.50% |
| Dec 31, 2024 | 6.45% |
| Sep 30, 2024 | -5.33% |
| Jun 30, 2024 | -6.63% |
| Mar 31, 2024 | -23.26% |
| Dec 31, 2023 | -17.27% |
| Sep 30, 2023 | -27.50% |
| Jun 30, 2023 | -47.16% |
| Mar 31, 2023 | -45.95% |
| Dec 31, 2022 | -39.13% |